Team:ULB-Brussels/Project
From 2014.igem.org
m |
|||
Line 52: | Line 52: | ||
<section style="margin: -25px"></section> | <section style="margin: -25px"></section> | ||
<section style="margin: 25px"> | <section style="margin: 25px"> | ||
- | <br/><font size="1"><b>Figure | + | <br/><font size="1"><b>Figure 1 </b> : PSK and plasmid addiction. Cells that inherit a plasmid encoding a TA system can grow normally. As there is no system to part plasmids equivalently in daughter cells, some cells might not receive a plasmid during division. Such cells would still have toxins and antitoxins in their cytosol but these will not be renewed due to the loss of TA genes. Antitoxins are often unstable and quickly degraded by a protease under these conditions, leaving the toxins free and able to kill the cell, effectively eliminating cells losing plasmids that encode TA systems.</font> |
</section> | </section> | ||
<br/> | <br/> | ||
Line 63: | Line 63: | ||
<section style="margin: -25px"></section> | <section style="margin: -25px"></section> | ||
<section style="margin: 25px"> | <section style="margin: 25px"> | ||
- | <br><font size="1"><b>Figure | + | <br><font size="1"><b>Figure 2 </b>: Type II TA systems. The toxin is a protein that inhibits a vital function of the cell (translation, replication, peptidoglycan synthesis, etc.) and the antitoxin is another protein that binds to this toxin, preventing it from causing harm to the cell. This antitoxin is often unstable and subject to a quick degradation. Should the transcription of the TA operon stops, the antitoxin would swiftly be degraded, allowing the toxin to kill or damage the cell. Type II TA operons are negatively regulated at the transcriptionnal level by their respective TA complexes.</font> |
</section></section> | </section></section> | ||
<section style=" margin: -30px"></section> | <section style=" margin: -30px"></section> | ||
Line 79: | Line 79: | ||
<section style="margin: -25px"></section> | <section style="margin: -25px"></section> | ||
<section style="margin: 25px"> | <section style="margin: 25px"> | ||
- | <br/><font size="1"><b>Figure | + | <br/><font size="1"><b>Figure 3</b> : DNA gyrase mechanism & CcdB poisoning. <b>a</b> : The DNA gyrase is a tetramer made of two GyrA and two GyrB subunits. <b>b</b> : An undefined DNAsegment (G-segment) can bind between two GyrB subunits. <b>c</b> : Another segment (T-segment) enters the GyrB clamps. <b>d</b> : Upon ATP biding, a conformationnal change occurs. It induces a double strand break in the G-segment and closes the GyrB clamps <b>e</b> : CcdB binds to GyrA subunits. <b>h</b> : CcdB prevents the gyrase from joining G-segment ends, resulting in DNA double strand breaks. <b>f</b> : The T-segment is released on the other side of the G-segment by an transitionnal state of GyrA subunits. <b>g</b> : ATP is hydrolysed to ligate the G-segment and to return the complex to its original conformation. The complex can start a new catalytic cycle of supercoiling.</font> |
</section> | </section> | ||
</section> | </section> | ||
Line 94: | Line 94: | ||
<p>The 2A sequences are short peptides (~18 amino-acids) encoded in some viral genomes. It allows the production of two different proteins from a single open reading frame : one upstream and one downstream of 2A peptide. This cleavage is done by ribosome skipping between the last amino-acid of the 2A peptide and the first amino-acid of the downstream protein, if this first amino-acid is a proline. The ribosome can then continue to translate the downstream sequence into a second, separated protein. Since the downstream protein does not necessarily begins by a prolin, we added the DNA sequence for the prolin at the end of the gene for the 2A peptide. This ensures that the 2A peptide will always be followed by a proline undependantely of the nature of the downstream protein. It is thus this construction of 2A peptide + proline that is referred to as "2A peptide" in the other sections of our project. Hence, the C-terminal extremity of the upstream protein is fused with the 2A peptide, and N-terminal extremity of the downstream protein is fused with the proline we added to the 2A peptide. <p> | <p>The 2A sequences are short peptides (~18 amino-acids) encoded in some viral genomes. It allows the production of two different proteins from a single open reading frame : one upstream and one downstream of 2A peptide. This cleavage is done by ribosome skipping between the last amino-acid of the 2A peptide and the first amino-acid of the downstream protein, if this first amino-acid is a proline. The ribosome can then continue to translate the downstream sequence into a second, separated protein. Since the downstream protein does not necessarily begins by a prolin, we added the DNA sequence for the prolin at the end of the gene for the 2A peptide. This ensures that the 2A peptide will always be followed by a proline undependantely of the nature of the downstream protein. It is thus this construction of 2A peptide + proline that is referred to as "2A peptide" in the other sections of our project. Hence, the C-terminal extremity of the upstream protein is fused with the 2A peptide, and N-terminal extremity of the downstream protein is fused with the proline we added to the 2A peptide. <p> | ||
A great advantage of the use of the 2A peptide over other methods is that it allows a powerful quality control: the antitoxin will be produced only and only if the upstream protein is correctly translated (or punctually muted, which is very rare). Any premature stop codon or “frame-shift” will be detected.</p> | A great advantage of the use of the 2A peptide over other methods is that it allows a powerful quality control: the antitoxin will be produced only and only if the upstream protein is correctly translated (or punctually muted, which is very rare). Any premature stop codon or “frame-shift” will be detected.</p> | ||
+ | <img src="https://static.igem.org/mediawiki/2014/4/45/2A.png> | ||
+ | <br/><font size="1"><b>Figure 4</b> : </font> | ||
<!-- This paragraph was yet written (with other sentences, same idea) in one precedent TA paragraph ! --> | <!-- This paragraph was yet written (with other sentences, same idea) in one precedent TA paragraph ! --> | ||
Line 106: | Line 108: | ||
<section style="margin: -25px"></section> | <section style="margin: -25px"></section> | ||
<section style="margin: 25px"> | <section style="margin: 25px"> | ||
- | <br/><font size="1"><b>Figure | + | <br/><font size="1"><b>Figure 5 </b>: |
Distinction between Toxin and Antitoxin Vectors: the plasmid on the left containing the toxin gene (when not added in the bacterial chromosome) and the second plasmid (regulated by the T7 constitutive promoter) containing the protein of interest (RFP/GFP marker) and the antitoxin gene. | Distinction between Toxin and Antitoxin Vectors: the plasmid on the left containing the toxin gene (when not added in the bacterial chromosome) and the second plasmid (regulated by the T7 constitutive promoter) containing the protein of interest (RFP/GFP marker) and the antitoxin gene. | ||
</font> | </font> |
Revision as of 21:11, 11 October 2014
$~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ \newcommand{\MyColi}{{\small Mighty\hspace{0.12cm}Coli}} \newcommand{\Stabi}{\small Stabi}$ $\newcommand{\EColi}{\small E.coli} \newcommand{\SCere}{\small S.cerevisae}\\[0cm] ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ \newcommand{\PI}{\small PI}$ $\newcommand{\Igo}{\Large\mathcal{I}} \newcommand{\Tgo}{\Large\mathcal{T}} \newcommand{\Ogo}{\Large\mathcal{O}} ~$
|
---|